Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Melanoma 19Squamous Cell Carcinoma of Head and Neck 18Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Lung Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3

Interventions

Ultrasonography 3Tomography, X-Ray Computed 2Colonoscopy 2Blood Specimen Collection 2tremelimumab 1peginterferon alfa-2a 1lenvatinib 1hepatitis C immune globulin, human 1fluoromisonidazole 1epigallocatechin gallate 1durvalumab 1babao dan 1Weights and Measures 1Vitamin B 6 1Urination 1Tomography 1Tidal Volume 1Tenofovir 1Surgical Procedures, Operative 1Standard of Care 1Shadowing Technique, Histology 1Rosuvastatin Calcium 1Radiotherapy 1Radiomics 1Propranolol 1Probiotics 1Preoperative Exercise 1Positron-Emission Tomography 1Portasystemic Shunt, Transjugular Intrahepatic 1Population Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Cirrhosis × tremelimumab × Clear all
NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

The University of Texas Health Science Center at San Antonio

Phase 2 Recruiting
32 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡